On Wednesday, Novo Nordisk A/S NVO reported gross sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (79.73 billion Danish Kroner).
Gross sales elevated by 30% in Danish kroner and at CER in comparison with 2023.
GLP-1 diabetes gross sales elevated by 12% at CER to 42.17 billion Danish kroner, and Weight problems care gross sales elevated by 91% at CER to 21.41 billion Danish kroner.
Ozempic sales elevated 12% to 33.85 billion Danish kroner, and Wegovy gross sales greater than doubled to 19.87 billion Danish kroner.
Insulin gross sales elevated 36% to fifteen.9 billion Danish kroner, and Uncommon illness gross sales elevated 25% at CER to five.71 billion Danish kroner.
Additionally Learn: RFK Jr. And Large Pharma: Well being Secretary Hopeful Solutions Pointed Questions On Medicine, Insurance coverage, Trump Exec Orders
The Danish pharmaceutical large’s internet revenue elevated by 29% to twenty-eight.23 billion kroner, with EPS of 6.34 Danish kroner, up 29%, beating the consensus of 5.82 Danish kroner. In USD phrases, EPS of $0.91 beat $0.83 consensus.
In its earnings launch, Novo Nordisk outlined its plans to conduct a brand new section 3 trial in 2025 to additional discover CagriSema’s weight-loss potential.
The outcomes from the second pivotal section 3 trial, REDEFINE 2, of CagriSema in adults with sort 2 diabetes and both weight problems or chubby are anticipated throughout the first quarter of 2025
To safe supply chain readiness, the corporate now expects to file for the primary regulatory approval of CagriSema throughout the first quarter of 2026.
Steerage: Novo Nordisk expects gross sales development of between 16% and 24% in fixed trade charges this 12 months, decrease than the 26% achieved in 2024.
“In 2025, we’ll proceed our concentrate on business execution, on the development of our early and late-stage R&D pipeline and on the growth of our manufacturing capability,” Chief Government Lars Fruergaard Jorgensen stated.
The corporate expects 2025 working revenue development of 19% to 27% in fixed trade charges.
Novo Nordisk provides that the outlook displays anticipated continued periodic provide constraints and associated drug scarcity notifications throughout a number of merchandise and geographies. Novo Nordisk is investing in inner and exterior capability to extend provide within the quick and long run.
Worth Motion: Ultimately test on Wednesday, NVO inventory was up 3.09% at $85.17 throughout the premarket session.
Learn Subsequent:
Picture by way of Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
